Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Free Cash Flow (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Free Cash Flow data on record, last reported at -$30.8 million in Q3 2025.

  • For Q3 2025, Free Cash Flow fell 42.2% year-over-year to -$30.8 million; the TTM value through Sep 2025 reached $52.2 million, up 161.76%, while the annual FY2024 figure was -$87.1 million, 5.29% down from the prior year.
  • Free Cash Flow reached -$30.8 million in Q3 2025 per STOK's latest filing, down from -$25.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $131.7 million in Q1 2025 and bottomed at -$30.8 million in Q3 2025.
  • Average Free Cash Flow over 4 years is -$8.4 million, with a median of -$21.6 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: plummeted 168.04% in 2023, then soared 635.87% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$22.1 million in 2022, then rose by 5.48% to -$20.9 million in 2023, then fell by 12.01% to -$23.4 million in 2024, then crashed by 31.51% to -$30.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$30.8 million in Q3 2025, -$25.3 million in Q2 2025, and $131.7 million in Q1 2025.